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doi:10.1016/j.ejvs.2011.03.034Abstract Objectives: This study aims to assess by biological markers the in vivo conse-
quences of foam sclerotherapy (FS) of saphenous veins. The secondary objective of this rando-
mised controlled trial (RCT) is to compare results of two randomised groups: with or without
post-treatment compression.
Patients and methods: Forty patients with incompetent great or small saphenous veins under-
went ultrasound-guided FS. Randomisation was conducted immediately after sclerotherapy to
two parallel groups, one (CG) with compression stockings and the other (WCG) without
compression.
A laboratory work-up was done on days 0 (before sclerotherapy), 1, 7, 14 and 28. The studied
markers were: fibrinogen, factor VIII, thrombomodulin, thrombineantithrombin complex,
D-dimers, platelet factor 4 and troponin.
Results: General data repartition was homogenous for CG and WCG. Twenty patients were
included in each group (females 90%; mean age 58 years). On day 28 (D28), the occlusion rate
of the veins was 100% in both groups. In all the samples (D0eD28), apart from a moderate
D-dimers’ increase at D1eD14, no significant biological change was observed in either the
WCG or the CG groups.
Conclusion: In terms of inflammation and coagulation, FS seems to have a minimal effect on
peripheral blood, either with or without post-treatment compression and does not appear to
have an effect on the myocardial risk.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Some in vitro effects of sclerotherapy have been described
in the literature, but issues have not been straightened out
so far. A Japanese study1 shows that polidocanol (POL) has
no effect on coagulation and inflammation, whereas for an
Australian author2,3 POL and sodium tetradecyl sulphate
(STS) may have either an anticoagulant or a procoagulant
effect, depending on the agent and the concentration used.31 43 34 34; fax: þ33 231 43 30 3
u (C.M. Hamel-Desnos).
ty for Vascular Surgery. PublisheIn vitro histology studies demonstrate that POL and STS
act on the varicose vein wall by attacking the endothelium
and even destroying it totally (disruption and loss of
endothelial cells).4,5
In vivo, inflammation of the vein, or even perivenous
tissue, is a continuation of this parietal aggression, and
a stage in the sclerosis of the varicose vein. Therefore, can0.
d by Elsevier Ltd. All rights reserved.
In Vivo Biological Effects of Foam Sclerotherapy 239we find biological signs of inflammation into the peripheral
blood?
The prevalence of thrombo-embolic events occurring
after sclerotherapy is estimated at 0.6%.6 Is there an acti-
vation of coagulation in the peripheral blood after
sclerotherapy?
Isolated cases have been published, arousing the suspi-
cion that sclerosing agents may have myocardial toxicity.7
Could a variation in troponin be detected in the circula-
tion after sclerotherapy?
We tried to provide elements of a reply to these questions
in our study, focussing on in vivo biological assessment after
foam sclerotherapy. We also thought it interesting to assess
the development of these parameters over time within and
between two randomised groups: post-sclerotherapy
compression versus non-compression.
Therefore, the main objective of our study was to
assess, in peripheral blood, the in vivo biological conse-
quences of foam sclerotherapy of saphenous veins.
The studied markers were markers of coagulation acti-
vation, fibrinolysis, endothelial lesion, platelet activation
and inflammation and troponin.
A secondary objective was to compare results of two
randomised groups: with or without post-treatment
compression using medical graduated elastic stockings.
Patients and Methods
The study design was a randomised, open, prospective
monocentre study with two parallel arms: one group
without compression (WCG) and one group with compres-
sion (CG) using stockings worn during the day for 3 weeks
following treatment.
Patients considered for inclusion in this study were those
presenting for treatment of symptomatic varicose veins. InTable 1 Exclusion criteria.
- Patient with a history of mental or psychiatric disorder or an
limiting the ability to participate in an informed manner and
- Voluntary Consent Form unsigned.
- Patients with isolated sapheno-femoral junction incompeten
- Patients with post-surgical recurrence of varices in the regio
saphenous vein or small saphenous vein without trunk recurr
- Patients with chronic liver disease.
- Renal failure (creatinine >150 mmol/l).
- Pregnant or nursing women.
- Women with a risk of pregnancy during treatment (absence o
- Physical or geographical impossibility of participation in the
- Patients with known progressive malignant disease.
- Patient with uncontrolled hypertension.
- Patient suffering from respiratory or cardiac failure.
- Patient with a history of deep vein thrombosis.
- Patients with known inherited or acquired coagulopathy.
- Patient with alcohol intolerance or having taken a blocking d
ethanol (Espe´ral for example) in the previous month.
- Patient with known allergy to LAUROMACROGOL 400.
- Patients with known patent foramen ovale (PFO).
- Patient presenting in the past with migraine or visual or othe
- Lycra allergy.
- Inability to apply elastic compression (e.g. osteoarthritis).total, 40 patients were included, of both sexes and varying
ethnicity, with a minimum age of 18 years, and who
suffered from incompetence of the great (GSV) or small
(SSV) saphenous vein.
Duplex ultrasound (DUS) examination was undertaken
with the patient in the standing position to assess the
competence of deep and superficial veins and establish the
extent of saphenous incompetence. Patients were consid-
ered suitable for treatment by foam sclerotherapy when
the trunk diameter was a maximum of 8 mm for the GSV and
6 mm for the SSV with venous reflux lasting at least 1 s, the
patient in the standing position. Clinical, etiologic,
anatomic and pathophysiologic (CEAP) classes, which were
included in this study, were C2seC6, Ep, As2, 4 and Pr with
level II examination.8 The exclusion criteria are listed in
Table 1.
Clinical and DUS results were also assessed to compare
the efficacy and side effects of foam sclerotherapy of the
saphenous veins with or without compression stockings.
Ethics
The study was approved by the French Ethical Research
Committee (Nord Ouest III CPP e.g., Comite´ de Protection
des Personnes, registered on 2 December 2006 under N
2006-22). It complies with the Declaration of Helsinki
(1964), according to its latest version (Hong Kong, 1989).
Sclerotherapy
Patients who gave informed written consent for their
inclusion in the study were investigated further. The scle-
rosant used was POL (Aetoxisclerol, manufactured by
Laboratoires Kreussler, Paris, France). Sclerosant foam was
obtained using a sterile disposable syringe kit includingy factor
compliant with the study.
ce without saphenous trunk incompetence of the thigh.
n of the great
ence in the thigh or calf.
f contraception).
study.
egradation of
r neurological disorders after sclerosing foam injection.
240 C.M. Hamel-Desnos et al.sterile air and the TurboFoam machine (kit and machine:
Kreussler Pharma, Wiesbaden, Germany). The sclerosant
liquid and air mixture was 1þ 4 (one volume of Aetoxi-
sclerolþ four volumes of air; i.e., ratio of 1/5). The
characteristics of the foam obtained were standardised and
these data have already been assessed and published:
bubble size of 1% Aetoxisclerol foam: 70e100 mm, 20 s
after preparing the foam.9
The sclerotherapy was guided by ultrasound and per-
formed by direct puncture with needle (22 Gauge, length of
40 mm, Terumo Leuven; Belgium), with the patient lying
recumbent. The volume of foam allowed per session was
between 2.5 and 8 ml for the GSV and between 2 and 5 ml for
the SSV, in accordance with European experts’ recommen-
dations (<10 ml per saphenous vein).10 The concentration
could be 1e2%, depending on the diameter of the vein.11 No
concomitant treatment was performed on other varices.
Follow-up examinations were performed during the 28-
day period following treatment. Patients were reviewed by
both clinical and DUS examinations on days 7, 14 and 28.
The aim of the day 7 examination was to investigate the
possibility that deep vein thrombosis had developed
following treatment. Visits and assessments on days 14 and
28 were performed by an independent expert, who was not
a member of the clinical team.
The criteria for efficacy of sclerotherapy were abolition
of saphenous reflux (as assessed by DUS), length of the
occlusion and diameter of the occluded vein, as assessed by
B-mode ultrasound imaging.
Randomisation
Randomisation for compression or no compression was
conducted after sclerotherapy using a randomisation list,
stratified by type of saphenous vein (small or great),
provided by the statistician.
Compression
Stockings used were certified medical grade compression,
Veinostim stockings grade 2 (French norm 15e20 mmHg),
provided by Laboratoire Pierre Fabre (Castres; France), and
complying with French Health Authorities recommenda-
tions. French Health Authorities (2010 report) recommend
a compression grade of 15e20 or 20e36 mmHg after scle-
rotherapy (or after surgery of varices).12
Compression hosiery was thigh length for GSV and knee
length for SSV.
Biology
Our choice of markers targeted various possible points of
impacts, that is, the endothelium, the platelets and the
coagulationefibrinolysis system:
- The best endothelial lesion marker is soluble throm-
bomodulin (TM);
- platelet activation marker: platelet factor 4 (PF4);
- coagulation and haemostasis activation markers:
 thrombineantithrombin complex (TAT): coagulation
activation; and D-dimers: activation of secondary fibrinolysis upon
the generation of fibrin;
- inflammation markers:
 fibrinogen; and
 Factor VIII (FVIII).
We also analysed troponin.
Therefore, the studied markers were: TM, PF4, TAT,
D-dimers, fibrinogen, FVIII and troponin.
Blood was collected on sodium citrated; after centrifu-
gation, platelet-poor plasma was frozen at 80 C and
stored until analysis.
During the course of the study, five blood samples per
patient were taken systematically, respectively on Day
0 (just prior to sclerotherapy) representing the baseline,
Day 1 (D1), D7, D14 and D28. A comparison was made
between the values obtained at baseline, D14 and D28 in
each CG and WCG group and between the two groups.Statistical analysis
The data were fed into SAS software.
An effectiveness analysis was performed of both populations
studied (intention to treat (ITT) and per protocol (PP)).
As for the intragroup analysis (before/after group
treatment) and the inter-group analysis (WCG versus CG),
the paired Student’s t-test (or the Wilcoxon test, paired in
the case of abnormality) was performed to detect quanti-
tative variables.
For general data, tests used were Fisher for sex, Wil-
coxon for age and body mass index (BMI), chi2 for laterality
and chi2 and Student for saphenous veins’ data and
repartition.
For biology, analysis was done from baseline (Student)
and between the two randomised groups (chi2 and Fischer).
The Wilcoxon test was also used to compare both groups’
results from baseline.
To indicate statistical significance, p-values should be
<0.05.Results
Forty patients were included in the study, performed
between January and June 2007, with 20 subjects in each
group. The general data of the populations were compa-
rable in both groups, there being no statistically significant
difference (Table 2).
Of the patients, 65% needed sclerotherapy of the GSV
and 35% of the SSV. The right leg was involved in 60% of
cases. There was no statistically significant difference
between the two groups.
A single sclerotherapy session was sufficient to obtain
occlusion of the saphenous vein in 100% of patients, using
moderate volumes of foam e an average of 4 ml for the
GSV and 3.6 ml for the SSV (extremes ranged from 2.5 to
7.5 ml) e without a statistically significant difference
between the two groups. The concentration used for
Aetoxisclerol was always 1%, except in the case of a single
patient, in whom a concentration of 2% was used (rates of
97.5% and 2.5%, respectively).
Table 2 General data (BMIZ body mass index; GSVZ great saphenous vein; and SSVZ small saphenous vein).
Without compression group, WCG Compression group, CG Total
Patients (n) 20 20 40
Sex 20 women (100%) 16 women (80%) 36 women (90%)
0 men (0%) 4 men (20%) 4 men (10%)
Age 58 (extr 33e76) 58.5 (extr 32e78) 58 (extr 32e78)
BMI 26.5 (extr 19e37) 27 (extr 21e38) 26 (extr 19e38)
Type of saphenous vein involved (n) GSV 13 GSV 13 GSV 26
SSV 7 SSV 7 SSV 14
Mean of GSV diameter (mm) 5.7 6 5.8
Median 5.5 (extr. 4e8) 6 (extr. 4e7.5) 5.75 (extr. 4e8)
Mean of SSV diameter (mm) 5 5 5
Median 4.5 (extr. 3.5e6) 4.5 (extr. 4.5e6) 4.5 (extr. 3.5e5.5)
Laterality Right Lower Limb 14 Right Lower Limb 12 Right Lower Limb 26
Left Lower Limb 6 Left Lower Limb 8 Left Lower Limb 14
Figure 1 Fibrinogen values (normal value 2.5e3.5 g/l). CG:
compression group; and WCG: without compression group.
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36 cm for the GSV (35 in the CG and 37 in the WCG) and 30 cm
for the SSV (26 in the CG and 33 in the WCG). The average
diameters of these veins after occlusion were 5.8 mm for the
GSV (6 mm for the CG and 5.7 mm for the WCG) and 5 mm for
the SSV (5.1 mm for the CG and 4.9 mm for the WCG).
Side effects were few with no statistical difference
between the two groups. Two minor asymptomatic
muscular thromboses, involving gastrocnemius veins (both
cases in the CG), and two banal superficial thrombophle-
bitis (one in the WCG and one in the CG) occurred. No
specific treatment was performed.
No pulmonary embolism, no deep or superficial vein
thrombosis, no neurological or chest symptom and no
cutaneous necrosis occurred.
Three intercurrent events occurred: one sinusitis in the
CG and one rhinitis and one viral sore throat in the WCG.
The medications taken were:
- sinusitis: non-steroidal anti-inflammatory for 3 days and
antibiotics for 6 days;
- sore throat: paracetamol for 5 days; and
- rhinitis: ibuprofen for 3 days.
Biological Results
A comparison was made between the values obtained at D0
(just prior to sclerotherapy) representing the baseline, D1,
D7, D14 and D28 in each CG and WCG group and between
the two groups.
A total of 199 blood samples and 1174 analyses were
performed. All samples were centralised and analysed in
the same laboratory (the Hemostasis Laboratory of the
Caen Centre Hospitalier Universitaire, France).
Values of the following dosages are reported: thrombo-
modulin, fibrinogen, FVIII, D-dimers, TAT, PF4 Platelet
factor 4 and troponin.
All TM values were <36 ngml1 (normal TM value:
42.1 11.3 ngml1).
Results from baseline (D0) to D28 are reported, for
fibrinogen, FVIII, D-dimers, TAT, PF4 and troponin, in Figs.
1e6, respectively.
The development of fibrinogen levels (Fig. 1) showed
a variation from the baseline that was only statisticallysignificant at D28 and in the WCG, with an average differ-
ence of 0.19 0.37 and pZ 0.0354. There was no differ-
ence between the two groups with respect to this
development.
On the other hand, with respect to the sample taken on
D14, a fibrinogen level of >3.5 g l1 was observed in only
20% of WCG patients, as against 57.9% in CG patients
(pZ 0.0259).
An analysis of the development of the FVIII level (Fig. 2)
takes account of the initial level of > or < 150%.
For patients with a rate of <150% prior to the procedure,
we note that, in the CG, there was an average increase of
7.59 11.14 (pZ 0.0126) at D1, whereas, in the WCG, the
only significant increase was observed at D28, with an
average increase of þ11.25 20.37 (pZ 0.0432).
In the group of patients whose initial FVIII rate was
>150%, we note that at D14, in the WCG, there was an
average reduction of 25.75 15.26, as against an average
increase of 5.67 6.66 in the CG (pZ 0.0220).
Results for both patients presenting with thrombosis of
gastrocnemius veins after sclerotherapy and for the three
patients presenting with intercurrent events are detailed in
Table 3.Discussion
Results show that there were few modifications of all
markers during the course of the study.
Figure 2 Factor VIII values (normal value <150%).
CG: compression group; and WCG: without compression group.
Figure 4 Thrombineantithrombin complex (TAT) values
(normal value <4 mg/ml). CG: compression group; and WCG:
without compression group.
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than 50% of patients having levels of >500 ngml1.
The distribution of values of D-dimers (Fig. 3) was very
heterogeneous in the two groups at different times in the
analysis: at D1, in WCG, the extreme values were 244 and
1713 ngml1 with a median at 514 ngml1; in CG, the same
dispersal was observed with extreme values of 227 and
1194 ngml1 and a median at 697 ngml1.
Although the variations were not statistically significant,
bycomparingthedevelopmentof the rateduring thecourseof
the study, it was observed that, if at D0, 20% of patients had
rates of D-dimers>500 ngml1, this percentage reached 60%
at D1 and D7, whereas it represented no more than 40% of
patients at D28.
Both patients presenting with thrombosis of gastrocne-
mius veins after sclerotherapy had an increase of D-dimers’
level, but the values were close to the normal range for one
of them. The second patient was already in the high normal
range (437 ngml1) at D0, that is, before sclerotherapy, and
his D-dimers’ level reached 1000 ngml1 at D28 (Table 3).
Despite the evidence of a significant increase in TAT
levels (Fig. 4) at D1 in both groups, only one patient in each
group had a level higher than normal.
The development of PF4 levels (Fig. 5) was identical in
both groups during the course of the study; a statistically
significant reduction in relation to the baseline was noticed
on D7.
For troponin (Fig. 6), assessed, as all other markers, at
D0 (just prior to sclerotherapy), D1, D7, D14 and D28, none
of the values were above the upper limit of normal.Figure 3 D-dimers values (normal value <500 ng/ml).
CG: compression group; and WCG: without compression group.We have not found an equivalent study in the literature.
Oh et al. assessed D-dimers’ level in the peripheral blood
of 12 patients after endovenous laser treatment: “Although
all D-dimer levels were within the normal range, D-dimer
levels immediately and on the 3rd day after the treatment
were in the high normal range. Subsequently, D-dimer was
decreased to the pre-treatment level by the 7th day.” 13
In a series of 20 cases, Hinterhuber reports that
a significant haemostatic activation after varicose vein
surgery was observed and persisted until 3 weeks post-
operatively.14 Markers TAT, thrombus precursor protein
(TPP), F1þ2, Plasmin Alpha 2 Antiplasmin complex (PAP),
D-dimers, tissue plasminogen activator (tPA) and plasmin-
ogen activator inhibitor1 (PAI1) were measured preopera-
tively and at D1, 2, 3, 7, 14 and 21.
Japanese authors have noticed a significant increase of
coagulation makers, especially for TAT, after sclerotherapy,
but the sclerotherapy was performed concomitantly to
surgery.15,16
In our study, where sclerotherapy was performed alone,
the statistical elements for the various parameters studied
did not make it possible to highlight the systemic activation
of vascular endothelium and platelets and plasma coagu-
lation. No inflammatory syndrome appeared following the
procedure. Only the D-dimers increased with, on D1 and D7,
more than 50% of patients having levels of >500 ngml1
(cut-off value for the exclusion of a thrombotic episode).Figure 5 Platelet Factor 4 (PF4) values (normal value
<10 IU/mL). CG: compression group; and WCG: without
compression group.
Figure 6 Troponin values (normal value <0.3 mg/L).
CG: compression group; and WCG: without compression group. Figure 7 D-dimers and varices surgery.14
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or after sclerotherapy thus develop in an overlapping
manner, with significant though fairly moderate elevation
during the first week post-procedure.Table 3 Biological results for the two patients presenting with g
three patients presenting with intercurrent events. nv: normal
bineantithrombin complex; PF4: platelet Factor; 4 CG: compress
Fibrinogen
nvZ 2.5e3.5 g/l
F VIII
nv <150%
D-dimers
nv <500
ng/ml
Patient N 1 101 (CG)
Gastrocnemius
thrombosis
D0 2.68 80 224.95
D1 2.73 81 671.35
D7 2.76 97 536.35
D14 2.93 102 413.45
D28 3,9 114 362,15
Patient N1 112 (CG)
Gastrocnemius
thrombosis
D0 2.88 116 436.7
D1 3.05 123 830.4
D7 2.79 116 988.25
D14 2.74 108 966.6
D28 2.63 93 1001
Patient N1 020 (CG)
Sinusitis D0 3.31 126 780.50
D1 3.53 124 829
D7 4.19 124 901
D14 3.82 116 843.5
D28 3.79 124 635
Patient N1 015 (WCG)
Viral sore throat D0 3.22 144 326.3
D1 3.17 142 674.25
D7 3.85 161 697.9
D14 3.28 141 533.65
D28 3.31 120 217.35
Patient N1 105 (WCG)
Rhinitis D0 3.23 113 136.3
D1 3.07 96 302.85
D7 3.05 72 311.65
D14 2.99 87 471.1
D28 3.04 112 209.35The same does not apply in the case of surgery, after
which the D-dimers rise very rapidly and significantly,
a return to normal only occurring after 3 weeks14 (Fig. 7).astrocnemius vein thrombosis after sclerotherapy and for the
value; FVIII: Factor VIII; TM: thrombomodulin; TAT: throm-
ion group; and WCG: without compression group.
TM nvZ 42.1 11.3
ng/ml
TATnv <4 mg/ml PF4nv <10 IU/ml
<36 0.1 5.6
<36 3 3.3
<36 1.1 10.1
<36 0.3 3.8
<36 0,4 2,7
<36 0.5 8.1
<36 5 11.7
<36 3 3.3
<36 1.2 15.4
<36 0.7 5.9
<36 <0.1 5
<36 2 3.2
<36 1 2.4
<36 1.2 3.5
<36 0.7 3.7
<36 2.8 10.2
<36 3.3 12.4
<36 1.2 7.4
<36 0.9 13.4
<36 2.9 8.5
<36 <0.1 13.6
<36 1.1 6.8
<36 0.8 7.9
<36 2.6 10.6
<36 <0.1 8.4
Table 4 Cost of the study.
Cost of the study V
Designing the study, developing
and implementing the
protocol, etc.
0
MDs investigator and experts 0
MDs biologists and teams 0
Document fees (booklet, etc) 1560
Ethics committee charges
(DRASS)
1450
Insurance fees 4508
Statistics 15,290
Reagents (biology) 19,728
Total 42,536
244 C.M. Hamel-Desnos et al.In our study, the changes in the various parameters were
identical in both groups of patients with or without post-
procedure compression.
In 1981, a Scandinavian study showed that “graduated
compression stockings have no effect on factor VIII or on
fibrinolytic activity.” 17
Finally, in our trial, no cardiac suffering was objectivised
through measuring the plasmatic troponin.
In 2010, Gillet et al. have suggested a pathophysiological
hypothesis for visual disturbances occurring after foam
sclerotherapy, resting on the release of endothelin.18
In 2011, Frullini gave confirmation of this hypothesis
(commentary of Peterson’s article).19
Our study was performed in 2007, previously to these
data; hence, we did not assess endothelin.
For information’s sake, we are providing the detailed
cost of this work in Table 4. The research required the
close, unpaid co-operation of a number of doctors and
biologists, as well as the help of paramedical staff, who
made themselves available on a frequent basis. Further-
more, there was excellent co-operation from the patients,
despite this research being of little individual direct benefit
to them.
Conclusion
Sclerosing foam, injected in effective doses, has a well-
targeted and localised action on the varicose vein being
treated. In terms of inflammation and coagulation, foam
sclerotherapy seems to have a minimal effect on peripheral
blood, either with or without post-treatment compression
and does not appear to have an effect on themyocardial risk.
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